表紙
市場調查報告書

人類肝臟模型世界市場∼2022年:創藥平台 (非酒精系脂肪性肝病患、肝臟機能晶片、2D模型、動物模型、生物3D列印)、地區分類預測

Human Liver Models Market by Drug Discovery Platform (Non-alcoholic Fatty Liver Organoids, Liver-on-a-chip, 2D Models, Animal Models, 3D Bioprinting), and Region (North America, Europe, Asia Pacific, Rest of the World) - Global Forecast to 2022

出版商 MarketsandMarkets 商品編碼 631686
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
人類肝臟模型世界市場∼2022年:創藥平台 (非酒精系脂肪性肝病患、肝臟機能晶片、2D模型、動物模型、生物3D列印)、地區分類預測 Human Liver Models Market by Drug Discovery Platform (Non-alcoholic Fatty Liver Organoids, Liver-on-a-chip, 2D Models, Animal Models, 3D Bioprinting), and Region (North America, Europe, Asia Pacific, Rest of the World) - Global Forecast to 2022
出版日期: 2018年04月26日內容資訊: 英文 39 Pages
簡介

世界人類肝臟模型市場2017年達13億5000萬美元、預計2022年可達25億6000萬美元、13.6%CAGR (年複合成長率) 成長。其中肝臟機能晶片 (Liver-on-a-chip) 最被期待今後可大幅成長。地區分類市場成長率比較、北美各國最高。市場成長主因是研究資金與創投增加、肝臟類器官相關研究活絡、(為了讓治療失敗損失最小化) 藥物毒性早期發現的必要性等。

本報告針對世界人類肝臟模型市場分析、提供市場基本構造與最新情況、主要市場促進、阻礙因素、市場動向預測 (過去3年、今後5年)、創藥平台分類、地區分類詳細動向、市場競爭狀態、主要企業檔案。

第1章 人類肝臟模型市場概要

  • 介紹
  • 市場動態
    • 促進因素
      • 動物實驗模型替代方法開發注目增加
      • 肝臟類器官開發的研究資金提供、創投
      • 肝臟類器官知名度提升需求增加
      • 非酒精系脂肪性肝病患者增加
      • 防止實驗在最終階段失敗造成財政損失、需求早期發見藥物毒性的必要性增加
    • 阻礙因素
      • 類器官與現有工作流程及合作相關課題
    • 市場機會
      • 創藥活動注意力增加
      • 肝臟移植需求增加
      • 亞太地區、拉丁美洲各國醫療市場擴大
    • 課題
      • 熟練專家不足

第2章 意見領袖見解 - 體外 (in vitro) 肝臟模型

第3章 人類肝臟模型市場:創藥平台分類

  • 介紹
    • 肝臟類器官
    • Liver-on-a-chip (肝臟機能晶片)
    • 2D模型
    • 動物模型
    • 生物3D列印

第4章 地區分類市場分析

  • 介紹
  • 北美:美國、加拿大
  • 歐洲
  • 亞太地區:中國、日本、印度
  • 其他國家 (RoW)
  • 作者情報
目錄
Product Code: BT 6218

"The human liver models market is projected to grow at a CAGR of 13.6% during the forecast period"

The global human liver models market is expected to reach USD 2.56 billion by 2022 from USD 1.35 billion in 2017, at a CAGR of 13.6%. Growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of liver models, growing initiatives to increase awareness about liver organoids, increasing research activities on liver organoids, increasing prevalence of non-alcoholic fatty liver disease, and growing need for the early detection of drug toxicity to minimize financial losses due to late-stage drug failure are expected to drive the growth of the human liver models market. However, issues related to the incorporation of organoids into existing workflows are expected to restrain the growth of this market to a certain extent.

"By type, the liver-on-a-chip segment is expected to grow at the highest rate during the forecast period"

Based on type, the market is segmented into liver organoids, liver-on-a-chip, 2D models, animal models, and 3D bioprinting. The liver-on-a-chip segment is expected to grow at the highest CAGR during the forecast period. This can be attributed to the simplicity of this model and the ability of on-chip hepatic tissues to maintain metabolic activity and phenotype similar to that of the in vivo environment. Moreover, the majority of the key players, research institutes, and government and non-government organizations are raising funds for the development of innovative liver-based models. In addition, key players operating in this market are entering into partnerships and collaborations with pharmaceutical companies to strengthen their market position. This strategy is enabling market players to evaluate the performance of their livers-on-a-chip offerings in drug development and other pharmaceutical research processes. Such funding initiatives from the government and private investors are expected to provide an impetus to market growth.

"The North American human liver models market is expected to grow at the highest CAGR during the forecast period"

North America is expected to witness the highest growth during 2017 to 2022, owing to well-established pharmaceutical and biotechnology industry and increasing government spending. Furthermore, growing initiatives to increase awareness about organoids and growing incidence of NAFLD is expected to boost the market.

Break of primary participants was as mentioned below:

  • By Company Type - Tier 1-50%, Tier 2-30% and Tier 3-20%
  • By Designation - C-level-30%, Director Level-48%, Others-22%
  • By Region - North America-48%, Europe-20%, Asia Pacific-25%, Row-7%

The key players in the global human liver models market are: Emulate (US), Ascendance Bio (US), HμREL (US), CN Bio (UK), Organovo (US), and Cyfuse Biomedical (Japan).

Research Coverage:

The report analyzes the human liver models market and aims at estimating the market size and future growth potential of this market based on various segments such as type and region. It provides detailed information regarding the major factors influencing the growth of this market and the regulatory analysis impacting market dynamics.

Reasons to Buy the Report:

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater share. Firms purchasing the report could use one or any combination of the below mentioned three strategies.

This report provides insights into the following pointers:

  • Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the human liver models market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various human liver models across regions
  • Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the human liver models market

TABLE OF CONTENTS

1. MARKET OVERVIEW FOR HUMAN LIVER MODELS

  • 1.1. INTRODUCTION
  • 1.2. MARKET DYNAMICS
    • 1.2.1. DRIVERS
      • 1.2.1.1. Growing focus on developing alternatives for animal testing models
      • 1.2.1.2. Significant increase in research funding and venture capital investments for the development of liver organoids
      • 1.2.1.3. Growing initiatives to increase awareness about liver organoids
      • 1.2.1.4. Increasing research activities on liver organoids
      • 1.2.1.5. Increasing prevalence of non-alcoholic fatty liver disease
      • 1.2.1.6. Growing need for the early detection of drug toxicity to minimize financial losses due to late-stage drug failure
    • 1.2.2. RESTRAINTS
      • 1.2.2.1. Issues related to the incorporation of organoids into existing workflows
    • 1.2.3. OPPORTUNITIES
      • 1.2.3.1. Increasing focus on drug discovery activities
      • 1.2.3.2. Rising demand for liver transplantation
      • 1.2.3.3. Growing healthcare market in the Asia Pacific and Latin America
    • 1.2.4. CHALLENGES
      • 1.2.4.1. Dearth of skilled professionals

2. INDUSTRY SPEAKS - IN VITRO LIVER MODELS

3. HUMAN LIVER MODELS MARKET, BY DRUG DISCOVERY PLATFORM

  • 3.1. INTRODUCTION
    • 3.1.1. LIVER ORGANOIDS
    • 3.1.2. LIVER-ON-A-CHIP
    • 3.1.3. 2D MODELS
    • 3.1.4. ANIMAL MODELS
    • 3.1.5. 3D BIOPRINTING

4. GEOGRAPHIC ASSESSMENT

  • 4.1. INTRODUCTION
  • 4.2. NORTH AMERICA
    • 4.2.1. US
    • 4.2.2. CANADA
  • 4.3. EUROPE
  • 4.4. ASIA PACIFIC
    • 4.4.1. CHINA
    • 4.4.2. JAPAN
    • 4.4.3. INDIA
    • 4.4.4. REST OF ASIA PACIFIC
  • 4.5. REST OF THE WORLD
  • 4.6. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: RESEARCH PROJECTS AND ACTIVITIES
  • TABLE 2: LIMITATIONS OF EXISTING CELL MODEL SYSTEMS
  • TABLE 3: SCIENTIFIC AND ETHICAL COMPARISON OF ANIMAL MODELS, HUMAN EMBRYO TISSUES, AND ORGANOID MODELS
  • TABLE 4: GLOBAL HUMAN LIVER MODELS MARKET, BY TYPE, 2015-2022 (USD MILLION)
  • TABLE 5: LIVER-ON-A-CHIP MARKET, BY REGION, 2015-2022 (USD THOUSAND)
  • TABLE 6: ANIMAL MODELS MARKET, BY REGION, 2015-2022 (USD MILLION)
  • TABLE 7: 3D BIOPRINTING MARKET, BY REGION, 2015-2022 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1: HUMAN LIVER MODELS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
  • FIGURE 2: NUMBER OF REGISTERED CLINICAL TRIAL STUDIES (2005-2017)
Back to Top